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Objective: Menstrual irregularity is one of the major complaints in women of reproductive age. The aim
of this study was to evaluate the complications in women with different menstrual disturbances.
Materials and methods: This is a retrospective study. A total of 576 women were screened ﬁrst, and 470
women were included later [257 women with oligo/amenorrhea (149 hyperandrogenic and 108 non-
hyperandrogenic women) and 213 normocyclic controls]. Endocrine and metabolic parameters and in-
sulin resistance were compared among different menstrual patterns.
Results: The average duration of menstrual cycle length was positively correlated with age, levels
of androgens and prolactin, lipid proﬁles, and the parameters of insulin resistance. Hyperandrogenic
women with amenorrhea had higher levels of androgens and more lipid proﬁles disorders than hyper-
androgenic womenwith oligomenorrhea. However, nonhyperandrogenic womenwith amenorrhea had a
degree of insulin resistance andmetabolic disturbance similar to that of nonhyperandrogenic womenwith
oligomenorrhea. Interestingly, for women with normal prolactin levels, serum prolactin levels were
signiﬁcantly lower in amenorrhea than oligomenorrhea in bothhyperandrogenic andnonhyperandrogenic
groups.
Conclusion: The degree of menstrual disturbances does not correlate with the severity of insulin resis-
tance and metabolic disturbances in women without excess levels of androgen. For women with normal
prolactin levels, amenorrheic patients had signiﬁcantly lower serum prolactin levels than oligomenor-
rheic patients.
Copyright  2014, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. All
rights reserved.Introduction
Hyperandrogenism and chronic anovulation are the major
components associatedwith polycystic ovary syndrome (PCOS). The
morbidity of PCOS is associated with insulin resistance, type 2
diabetes mellitus, hypertension, dyslipidemia, cardiovascular dis-
ease, and low-grade chronic inﬂammation [1]. A recently reviewed
study found that not all womenwith PCOS should be considered asedicine, Wan Fang Hospital,
inglong Road, Taipei 11696,
u).
.
bstetrics & Gynecology. Publishedbeing similar in terms of cardiovascular risk proﬁles [2]. Irregular
menstrual cycles are associated with insulin resistance [3] and
increased risk of cardiovascular disease [4]. Ovulatory dysfunction
is associatedwith awide range ofmenstrual disturbances, including
irregular cycles and clinical amenorrhea. Menstrual disorders are
easy-to-use parameters in the clinical setting. Amenorrhea and
oligomenorrhea represent different types of menstrual distur-
bances. However, the correlation between menstrual interval and
biochemical parameters remains unclear in women with chronic
anovulation. The association between the severity of menstrual
disorders and endocrine and metabolic parameters is controversial
[3e7]. We conducted this retrospective study to examine the rela-
tionship betweenmenstrual disorders and themetabolic syndrome
(MBS).by Elsevier Taiwan LLC. All rights reserved.
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We retrospectively reviewed the medical records of female pa-
tients who visited the Reproductive Endocrinology Clinic at the
Wan FangMedical Center at Taipei Medical University from January
1, 2009 to November 31, 2011. The chief complaints of these pa-
tients were menstrual disturbance, dysmenorrhea, infertility, and
acne/hirsutism. The following patients were excluded: (1) women
who had been diagnosed with congenital adrenal hyperplasia,
androgen-secreting tumor, Cushing’s syndrome, disorders of the
uterus (e.g., myoma, adenomyosis, Asherman’s syndrome, Mülle-
rian agenesis), and chromosomal anomalies (e.g., Turner syn-
drome); (2) womenwho had hadmenarche less than 3 years before
evaluation or who were older than 46 years; (3) women with
inadequate clinical/biochemical records; and (4) women who
received hormones or drugs for major medical diseases. A total of
576 women were initially screened.
Modiﬁed FerrimaneGallwey (mFeG) scores were recorded by
one investigator. Hirsutism was deﬁned as an mFeG score  6.
Biochemical hyperandrogenemia was deﬁned as total serum
testosterone  2.78 mmol/L. Hyperandrogenism was deﬁned as
hirsutism and/or biochemical hyperandrogenemia.
Amenorrheawas deﬁned as nomenstrual bleeding over a period
of at least 3 months and oligomenorrhea was deﬁned as fewer than
nine cycles per year [8]. Normocyclic controls were deﬁned as hav-
ing regular menstrual intervals of 24e34 days. To simplify the
experimental groups, 106 women were further excluded due to
primary amenorrhea (N ¼ 9), premature ovarian failure (N ¼ 10),
hyperprolactinemia (serum prolactin > 26.4 mg/L or 1.15 nmol/L;
N ¼ 59), and irregular cycles without oligomenorrhea/amenorrhea
(N ¼ 28). Finally, the 470 women were classiﬁed into three sub-
groups, namely, normocyclic (N ¼ 213) and oligomenorrhea/
amenorrhea (N ¼ 257; 147 women had oligomenorrhea and 110
women had amenorrhea). To further evaluate the clinical and
biochemical characteristics of women with amenorrhea and oligo-
menorrhea, the 257 women were classiﬁed as hyperandrogenic
(N ¼ 149, oligomenorrhea ¼ 83, amenorrhea ¼ 66) and non-
hyperandrogenic (N¼108, oligomenorrhea¼64, amenorrhea¼44).
PCOS was diagnosed according to the 1990 National Institutes of
Health diagnostic criteria, which required both oligomenorrhea or
amenorrhea and hyperandrogenism for a diagnosis of PCOS. Of the
470 cases, 149 women with PCOS and 321 women without PCOS
were considered separately.
The number of menstrual cycles during the previous year was
recorded. Menstrual cycle length was deﬁned as the average
duration/year. Body mass index was deﬁned as body weight in ki-
lograms divided by body height in meters squared (kg/m2).
Medical histories included detailed menstrual and medical/
surgical records as well as anthropometric measurements. The
dates and assays for blood sampling have been previously
described [9]. The timing of blood sampling was either in the early
follicular phase (Days 1e5 for normocyclic women) ormore than 35
days after the previous menstrual bleeding (for oligo/amenorrheic
women). The following components were evaluated: (1) total
testosterone, androstenedione, dehydroepiandrosterone sulfate,
17-a-hydroxyprogesterone, and free androgen index (FAI); FAI ¼ T
(nmol/l)  100/sex hormone-binding globulin (SHBG) (nmol); (2)
fasting insulin, fasting glucose, 2-hour oral glucose tolerance test
glucose level, and the homeostasis model assessment of insulin
resistance index (HOMA-IR); HOMA-IR ¼ [fasting insulin (mU/
mL)  fasting glucose (mg/dL)]/405; (3) serum thyroid-stimulating
hormone (TSH), follicle-stimulating hormone (FSH), luteinizing
hormone (LH), and prolactin; (4) total cholesterol, triglycerides
(TGs), high-density lipoprotein (HDL), and low-density lipoprotein
(LDL); and (5) SHBG and anti-Müllerian hormone (AMH).The MBS (2005 National Cholesterol Education Program-Adult
Treatment Panel III) was deﬁned as the presence of at least three of
the following criteria: abdominal obesity (waist circumference >
80 cm), serum TG  1.7 mmol/L, serum HDL < 1.3 mmol/L, blood
pressure130/85mmHg,and fastingplasmaglucose5.6mmol/L.
Statistical analysis
Statistical analysis was performed using SPSS 13.0 for Windows
(SPSS, Inc., Chicago, IL, USA). We evaluated the correlation between
menstrual cycle length and PCOS-related parameters with Pear-
son’s correlation coefﬁcients using the two-tailed method. Data are
presented as the mean  standard deviation. We used the Chi-
square and Fisher’s exact tests to compare categorical variables
and analysis of variance to compare continuous variables (Tables 1
and 2). Differences between the groups were considered signiﬁcant
when p < 0.05.
Results
The average duration of menstrual cycle length was positively
correlated with the following parameters: age (r ¼ 0.133,
p ¼ 0.004), AMH (r ¼ 0.199, p < 0.001), SHBG (r ¼ 0.174,
p < 0.001), ferritin (r ¼ 0.319, p < 0.001), LH (r ¼ 0.123, p ¼ 0.008),
prolactin (r ¼ 0.217, p < 0.001), HOMA-IR (r ¼ 0.234, p < 0.001),
fasting insulin (r ¼ 0.220, p < 0.001), total cholesterol (r ¼ 0.207,
p < 0.001), LDL (r ¼ 0.200, p < 0.001), total testosterone (r ¼ 0.169,
p < 0.001), androstenedione (r ¼ 0.169, p < 0.001), and FAI
(r ¼ 0.165, p < 0.001).
Table 1 shows the clinical and biochemical characteristics of 470
patients. The normocyclic group (A) had 213 cases and the oligo/
amenorrhea group (B) had 257 cases. Compared with the controls,
the women with oligo/amenorrhea had a higher prevalence of
hyperandrogenism and MBS. Women with oligo/amenorrhea suf-
fered from higher disturbances in the parameters of insulin resis-
tance and lipid proﬁles than women with normal menstrual cycle.
Table 2 shows biochemical and clinical characteristics of nor-
mocyclic controls and oligo/amenorrhea in women without PCOS.
The LH/FSH ratio was signiﬁcantly higher in women with oligome-
norrhea/amenorrhea than in women with normal cycle (Table 2);
however, the LH/FSH ratio was not signiﬁcantly different between
women with oligomenorrhea and women with amenorrhea
(Table 2). Androgens levels (total testosterone, androstenedione,
and FAI), lipid proﬁles, and insulin resistance were similar between
oligomenorrheic and amenorrheic women without PCOS (Table 2).
Table 3 shows the comparison of biochemical characteristics of
PCOS women with oligomenorrhea or amenorrhea. For PCOS,
amenorrheic women had signiﬁcantly higher androgens, lower
SHBG levels, and more lipid proﬁle disturbances than oligome-
norrheic women. In both the PCOS and non-PCOS groups, the in-
sulin resistance and risk of MBS were not signiﬁcantly different
between the oligomenorrheic and amenorrheic subgroups
(Tables 2 and 3). Interestingly, serum prolactin levels were signiﬁ-
cantly higher in oligomenorrheic compared with amenorrheic
women for both PCOS and non-PCOS.
Discussion
Ovulatory dysfunction, deﬁned as oligomenorrhea and amenor-
rhea, is a commoncomplaint inwomenof reproductive age. The long-
term complications of ovulatory dysfunction have not been well
studied. Hyperandrogenemia is thought to increase cardiovascular
and metabolic risks in women with PCOS [2,5]. Our results showed
that serumandrogenswere correlatedwith the severity ofmenstrual
disturbances. Therefore, we compared the clinical and biochemical
Table 2
Biochemical and clinical characteristics of normocyclic controls and oligo/amenorrhea in women without PCOS.
Normocyclic control Oligomenorrhea Amenorrhea A vs. B A vs. C B vs. C
A B C
Case number 213 64 44
Age (y) 28.7  6.4 28.5  6.8 27.4  5.7 0.998 0.456 0.730
Menarche (y) 12.6  1.4 12.8  1.7 12.6  1.3 0.646 1.000 0.781
Number of cycles per year 11.7  0.9 6.6  1.3 2.4  1.1 <0.001* <0.001* <0.001*
BMI (kg/m2) 24.4  6.0 24.7  5.7 24.4  7.4 0.981 1.000 0.995
SHBG (nmol/L) 50.5  32.8 45.2  24.9 41.4  26.2 0.430 0.137 0.828
Metabolic syndrome (%) 20 26 33 0.742 0.327 0.868
Androgens
Total testosterone (nmol/L) 1.9  1.0 1.8  0.6 1.8  0.6 0.735 0.936 0.988
Androstenedione (nmol/L) 82.6  44.9 85.6  35.5 88.1  36.9 0.925 0.762 0.977
FAIa 6.5  7.9 5.5  4.0 6.5  4.5 0.446 1.000 0.556
Insulin sensitivity
Fasting insulin (pmol/L) 68.8  66.2 82.5  63.6 98.7  95.1 0.357 0.147 0.692
Fasting glucose (nmol/L) 5.2  1.3 5.1  0.7 5.2  1.0 0.757 1.000 0.933
2-hour glucose (nmol/L) 6.3  2.9 6.3  2.4 6.6  2.8 1.000 0.865 0.915
HOMA-IR 2.4  2.5 2.8  2.5 3.8  5.6 0.546 0.286 0.618
Hormonal components
TSH (mIU/L) 1.8  1.1 2.1  1.2 2.0  1.2 0.333 0.586 0.999
FSH (IU/L) 6.3  2.2 6.1  2.4 6.6  2.4 0.971 0.730 0.641
LH (IU/L) 5.1  2.6 9.1  7.0 9.2  7.5 <0.001* 0.002* 1.000
LH/FSH 0.9  0.5 1.6  1.2 1.4  0.9 <0.001* 0.007* 0.552
Prolactin (nmol/L) 0.65  0.01 0.64  0.25 0.46  0.19 0.998 <0.001* <0.001*
Lipid proﬁles and blood pressure
Cholesterol (mmol/L) 4.6  0.8 5.1  0.8 5.4  0.9 0.001* <0.001* 0.210
Triglycerides (mmol/L) 0.9  0.7 1.2  1.0 1.2  1.0 0.207 0.160 0.980
HDL (mmol/L) 1.4  0.4 1.4  0.4 1.5  0.5 0.999 0.219 0.320
LDL (mmol/L) 2.7  0.77 3.1  0.8 3.2  0.8 0.001 0.001* 0.991
Data are either mean  standard deviation or percentage.
*p < 0.05.
BMI ¼ body mass index; FSH ¼ follicle-stimulating hormone; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeostasis model assessment of insulin resistance index;
LDL ¼ low-density lipoprotein; LH ¼ luteinizing hormone; PCOS ¼ polycystic ovary syndrome; SHBG ¼ sex hormone-binding globulin; TSH ¼ thyroid stimulation hormone.
a FAI ¼ Free Androgen Index, which is calculated as T (nmol/l)  100/SHBG (nmol).
Table 1
Biochemical and clinical characteristics of normocyclic controls and oligo/amenorrhea.
Total Normocyclic control Oligo/amenorrhea p
A B A vs. B
Case number 470 213 257
Age (y) 27.7  6.4 28.7  6.4 27.0  6.3 0.012*
BMI (kg/m2) 25.4  6.6 24.4  6.0 26.2  6.9 0.006*
SHBG (nmol/L) 42.8  29.0 50.5  32.8 36.4  23.5 <0.001*
Hyperandrogenism (%) 49 38 58 <0.001*
Metabolic syndrome (%) 29 20 35 0.001*
Androgens
Total testosterone (nmol/L) 2.17  1.04 1.87  1.03 2.42  0.99 <0.001*
Androstenedione (nmol/L) 93.0  44.2 82.6  44.9 101.7  41.8 <0.001*
FAIa 8.54  8.48 6.51  7.93 10.22  8.56 <0.001*
Insulin sensitivity
Fasting insulin (pmol/L) 89.6  91.8 68.8  66.2 106.5  105.3 <0.001*
Fasting glucose (nmol/L) 5.18  1.04 5.20  1.28 5.15  0.80 0.949
2-hour glucose (nmol/L) 6.43  2.66 6.31  2.91 6.52  2.45 0.795
HOMA-IR 3.15  3.72 2.39  2.54 3.76  4.36 <0.001*
Hormonal components
TSH (mIU/L) 1.96  1.17 1.82  1.12 2.07  1.20 0.053
FSH (IU/L) 6.30  2.11 6.25  2.21 6.33  2.03 0.968
Prolactin (nmol/L) 0.61  0.03 0.65  0.01 0.58  0.02 0.003*
Lipid proﬁles and blood pressure
Cholesterol (mmol/L) 4.81  0.90 4.60  0.83 4.98  0.92 <0.001*
Triglycerides (mmol/L) 1.04  0.81 0.92  0.69 1.14  0.88 0.008*
HDL (mmol/L) 1.36  0.42 1.38  0.42 1.35  0.42 0.772
LDL (mmol/L) 2.90  0.81 2.69  0.74 3.07  0.82 <0.001*
Data are either mean  standard deviation or are percentage.
*p < 0.05.
BMI ¼ body mass index; FSH ¼ follicle-stimulating hormone; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeostasis model assessment of insulin resistance index;
LDL ¼ low-density lipoprotein; SHBG ¼ sex hormone-binding globulin; TSH ¼ thyroid stimulation hormone.
a FAI ¼ Free Androgen Index, which is calculated as T (nmol/l)  100/SHBG (nmol).
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Table 3
A comparison of biochemical characteristics of oligomenorrheic or amenorrheic women with PCOS.
Total Oligomenorrhea Amenorrhea Oligo- vs. amenorrhea
Case number 149 83 66 p
Age (y) 26.2  6.1 26.6  5.9 25.7  6.4 0.371
Menarche (y) 12.5  1.5 12.7  1.5 12.4  1.4 0.171
Number of cycles per year 4.7  2.4 6.5  1.2 2.5  1.2 <0.001*
BMI (kg/m2) 27.4  7.0 27.5  7.6 27.4  6.2 0.981
PCOM 69% 61% 79% 0.023*
SHBG (nmol/L) 31.2  20.6 35.1  23.4 26.3  15.2 0.009*
Anti-Müllerian hormone (ng/mL) 8.5  5.5 8.0  5.3 9.2  5.7 0.207
Anthropometric measurements
Weight (kg) 70.3  19.3 70.6  20.9 69.9  17.2 0.819
Height (cm) 159.8  5.4 160.1  5.7 159.3  5.0 0.379
Waist (cm) 89.2  17.2 88.3  17.4 90.2  17.0 0.493
Hip (cm) 102.9  12.1 103.2  12.9 102.6  11.1 0.758
Waist to hip ratio 0.86  0.09 0.85  0.08 0.87  0.09 0.098
Androgens
Total testosterone (nmol/L) 2.9  1.0 2.7  1.0 3.1  0.9 0.009*
Androstenedione (nmol/L) 112.6  42.5 105.7  39.5 121.2  44.9 0.027*
FAIa 13.3  9.5 11.8  10.1 15.3  8.5 0.026*
DHEA-S (nmol/L) 634.2  274.2 653.2  274.0 610.3  274.6 0.344
17-OH PRG (nmol/L) 0.034  0.019 0.034  0.022 0.035  0.017 0.759
Insulin sensitivity and glucose tolerance
Fasting insulin (pmol/L) 119.1  120.0 109.7  112.5 130.8  128.7 0.288
Fasting glucose (nmol/L) 5.2  0.8 5.2  0.7 5.2  0.9 0.830
Two-hour glucose (nmol/L) 6.6  2.4 6.5  2.2 6.7  2.6 0.521
HOMA-IR 4.2  4.6 3.8  4.1 4.6  5.1 0.282
Hormonal components
TSH (mIU/L) 2.1  1.2 1.9  1.1 2.3  1.3 0.073
LH (IU/L) 12.2  9.4 11.6  7.0 12.9  11.8 0.380
FSH (IU/L) 6.3  1.7 6.4  1.7 6.2  1.8 0.421
LH/FSH 2.3  3.8 2.2  2.9 2.5  4.7 0.675
Prolactin (nmol/L) 0.59  0.20 0.62  0.20 0.55  0.18 0.018*
Lipid proﬁles and blood pressure
Cholesterol (mmol/L) 4.8  0.9 4.7  0.8 5.0  1.0 0.112
Triglycerides (mmol/L) 1.1  0.8 1.0  0.6 1.3  1.0 0.023*
HDL (mmol/L) 1.3  0.4 1.3  0.4 1.2  0.4 0.028*
LDL (mmol/L) 3.0  0.8 2.9  0.7 3.2  0.9 0.013*
Metabolism
Metabolic syndrome 40% 37% 45% 0.327
Hypertension 38% 35% 42% 0.415
HDL < 1.3 mmol/L 57% 51% 65% 0.076
Triglycerides  1.7 mmol/L 13% 10% 18% 0.130
Waist > 80 cm 63% 61% 65% 0.604
FPG  5.6 mmol/L 21% 22% 20% 0.768
Data are either mean  standard deviation or are percentage.
*p < 0.05.
17-OH PRG ¼ 17-a-hydroxyprogesterone; BMI ¼ body mass index; DHEA-S ¼ dehydroepiandrosterone sulfate; FPG ¼ fasting plasma glucose; FSH ¼ follicle-stimulating
hormone; HDL ¼ high-density lipoprotein; HOMA-IR ¼ homeostasis model assessment of insulin resistance index; LDL ¼ low-density lipoprotein; LH ¼ luteinizing hormone;
PCOS ¼ polycystic ovary syndrome; SHBG ¼ sex hormone-binding globulin; TSH ¼ thyroid stimulation hormone.
a FAI ¼ Free Androgen Index, which is calculated as T (nmol/l)  100/SHBG (nmol).
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with amenorrhea and oligomenorrhea. Hyperandrogenic women
witholigo/amenorrheamet thediagnostic criteria of PCOS [10]. In the
hyperandrogenic (PCOS) subgroup, women with amenorrhea had
higher androgen levels and lipid proﬁle disturbances. We found that
the degree of cycle irregularity correlated with the severity of endo-
crine and/or metabolic disorders, and this result was consistent with
previous reports [6,7]. However, in nonhyperandrogenic women, all
of the parameters related to androgens, lipid proﬁles, insulin resis-
tance, and metabolic complications were similar between women
with amenorrhea and women with oligomenorrhea. Therefore, it
appears that the degree ofmenstrual disturbances does not correlate
with the severity ofmetabolic disturbances inwomenwithout excess
levels of androgen.
The LH/FSH ratio was signiﬁcantly higher in oligomenorrheic/
amenorrheic women than in normal cyclic women as previous
reports suggested [11]; however, the level of LH/FSH ratio was not
signiﬁcantly different between oligomenorrheic and amenorrheic
women. Our study showed that LH/FSH ratio was not a predicative
marker for the severity of menstrual disturbance in women witholigomenorrhea. Comparing women with PCOS, amenorrheic
women had signiﬁcantly higher level of androgens than oligome-
norrheicwomen. However, for womenwithout PCOS, the androgens
levels were similar between the oligomenorrheic and amenorrheic
groups. Higher androgens levels were associated with more men-
strual disturbance in women with PCOS but not in women without
PCOS.
The most interesting ﬁnding in our study was the correlation
between serum prolactin levels and menstrual interval. Because
hyperprolactinemic women had been excluded initially, the pro-
lactin levels in our patients were all within the normal range. We
found a strongly negative correlation between menstrual interval
and serum prolactin levels. Prolactin was the only parameter that
signiﬁcantly differed between women with oligomenorrhea and
amenorrhea in both the hyperandrogenic and nonhyperandrogenic
subgroups. A previous study of 246 hyperprolactinemic women
found that patients with amenorrhea had signiﬁcantly higher
serum prolactin levels than patients with oligomenorrhea [12]. We
found, however, that amenorrheic women with normal prolactin
levels presented with lower prolactin levels than oligomenorrheic
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anovulation rather than oligomenorrhea, it might implicate a
different pathological pathway of ovulatory disturbance between
women with and without hyperprolactinemia. This situation has
not been previously reported and warrants further study.
This is a retrospective study; data were obtained from medical
records reviewed in outpatient clinics, and the patients were Asian
women. The results in this study should be applied with caution
due to sampling limitations.
Conclusion
The degree of menstrual disturbances did not correlate with the
severity of insulin resistance and metabolic disturbances inwomen
without androgen excess. For womenwith normal prolactin levels,
amenorrheic patients had signiﬁcantly lower serum prolactin levels
than oligomenorrheic patients.
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